Affymax affymax.com


Public list: Smart Money VCs (6328) Pharma Startups (4734) Cancer Therapeutics (1145)

Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The companys product candidate, Hematide, is currently in Phase 3 trials for the treatment of anemia associated with chronic renal failure. Anemia is a serious condition in which blood is deficient in red blood cells and hemoglobin. It is common in patients with chronic renal failure, cancer, heart failure, inflammatory diseases and other critical...Show all

Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The companys product candidate, Hematide, is currently in Phase 3 trials for the treatment of anemia...Show all

Company (Alive / Active)

Phone: 650-812-8700

Fax: (650) 424-0832

4001 Miranda Avenue/4015 Miranda Avenue

Palo Alto, 94304
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Affymax $100M Jul 14, 2005
Amgen $0M Jan 1, 1983

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Affymax Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Peptides that bind to the erythropoietin receptor Nov 12, 2010 May 20, 2014 Patent
Spacer moiety for poly(ethylene glycol) modified peptide based compounds Apr 04, 2011 Nov 26, 2013 Patent
Erythropoietin receptor peptide formulations and uses Jul 23, 2008 Dec 04, 2012 Patent
Peptides that bind to the erythropoietin receptor Mar 17, 2009 Nov 06, 2012 Patent
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules Jan 30, 2008 Jan 31, 2012 Patent
See all 16 patents